TP53 and cancer: Since the majority of the traditional chemotherapeutic reagents induce DNA damage by triggering a p53 response [54], cap-dependent inhibitors or chemical compounds that specifically regulate expression of p53 ITAFs may replace some of these DNA damaging agents in cancer treatment, which may reduce toxic side effect and drug resistance causing by DNA damaging drugs in chemotherapy.